Posted on

Testosterone Therapy, a Personal Experience – Sally’s Story

Just over 2 years ago I had a vaginal hysterectomy for a prolapsed womb, cystocele and retrocele repair. Post operative pain from the retrocele repair went on for a year due to scar tissue making sex painful and then a few months after the surgery my sex drive went completely. Despite keeping my ovaries blood tests revealed that my oestrogen and testosterone levels had completely flatlined. The hysterectomy had caused my ovaries to stop working altogether. Continue reading Testosterone Therapy, a Personal Experience – Sally’s Story

Posted on

Balancing testosterone in women naturally

You may or may not be aware that the NHS have recently removed Testosterone implants from the NHS prescription lists. Whilst it may be possible to pay for a private prescription these are expensive and potentially unnecessary. Testosterone in women helps to regulate mood and libido and it’s production continues mostly unaffected by the menopause, unlike oestrogen and progesterone.  In addition to these benefits for women post menopause it also supports the immune system and assists the body in the production of muscle tissue as well as helping to boost your appetite. Continue reading Balancing testosterone in women naturally

Posted on

Is Menopause a Risk Factor for Developing Diabetes?

Levels of diabetes are increasing and so are levels of pre-diabetes/glucose intolerance. Some research has suggested that the menopause may be a factor, particularly the high levels of testosterone that some women can develop post menopause.  These high levels can occur post menopause because the other two female sex hormones reduce their production levels whilst testosterone remains roughly the same. Continue reading Is Menopause a Risk Factor for Developing Diabetes?

Posted on

Intrinsa Testoserone Patch Denied By SMC

The Scottish Medicines Consortium have today issued guidance denying the use of the testosterone patch Intrinsa saying “Testosterone transdermal patch (Intrinsa) for the treatment of hypoactive sexual desire disorder (HSDD) in surgically induced menopausal women. The manufacturer did not present a sufficiently robust economic analysis to gain acceptance by SMC.” You can read the complete statement of Final Advice on their website at: scottishmedicines.org.uk/smc/5512.html